Abidol was Selected into the National Health Commission's Influenza Diagnosis and Treatment Program

Since the beginning of winter, influenza activity has risen rapidly. In order to ensure the smooth and orderly progress of national influenza medical work and effectively protect the people's health, on November 13, the National Health Commission issued the influenza diagnosis and treatment plan (2019 version), giving authoritative suggestions for the diagnosis and treatment of influenza this winter and next spring. Abidol capsule produced by Shijiazhuang No. 4 Pharmaceutical Co., Ltd. was included in the list and was selected as the recommended drug in the treatment plan for influenza.


Influenza is an acute respiratory infectious disease caused by influenza virus, which is generally susceptible to the whole population. Because influenza virus is easy to mutate and spread rapidly, it can cause seasonal epidemic every year. At present, there are three kinds of anti influenza drugs approved for marketing in China, including neuraminidase inhibitor, haemagglutinin inhibitor and M2 ion channel blocker. Abidol included in the new influenza diagnosis and treatment plan is one of the haemagglutinin inhibitors, which can effectively block the fusion of virus and host cell, at the same time, it can induce the body to produce endogenous interferon, interfere with virus replication and improve the mechanism. It can enhance the phagocytic function of macrophages and induce the activation of natural killer cells. It has antiviral effect on all kinds of influenza viruses (A, B, C), especially on influenza A viruses (H1N1, H2N2, H3N3). The safety is high and the side effect is slight. So far, no drug-resistant strains have been found. After years of clinical validation, Abidor has become an essential drug for influenza prevention and control in Russia, and also a strategic reserve drug for the military.


Abidol has been widely recognized in the medical community. Before it was included in the new influenza diagnosis and treatment plan, Abidol was selected into the diagnosis and treatment plan for influenza A (H1N1) (2010) issued by the former Ministry of Health. In addition, the respiratory branch of the Chinese Medical Association and the pediatric branch of the Chinese Medical Association jointly published the consensus of Chinese experts on the treatment and prevention of antiviral drugs for influenza (2016) and the consensus of experts on the rational application of antiviral drugs for influenza (2016) issued by the respiratory branch of the Chinese Medical Association in 2016. It is recommended to be commonly used antiviral drugs for influenza.


Abidol hydrochloride capsule manufactured by Shijiazhuang No. 4 Pharmaceutical Co., Ltd. has been listed in the domestic market for many years and is favored by the market. In the brand competition pattern of public medical institutions and urban retail pharmacies, there are only four drugs in the top three. Enoda ® won the title of "the most innovative pharmaceutical product in China in 2019". In November, it was also selected as "the 70th anniversary of the founding of new China · the landmark achievements of Chinese Pharmaceutical Science and technology" by the Southern Economic Research Institute of the State Food and drug administration.

Key words: